Comparison of combined, stepwise sequential, contingent, and integrated screening in 7292 high‐risk pregnant women

To compare the efficacy of combined, stepwise sequential, and contingent screening versus the integrated test in detecting fetal aneuploidies.

[1]  A. Albert.  Chorionic gonadotropin , 2016, Reactions Weekly.

[2]  L. Dugoff,et al.  Aneuploidy screening: a position statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, January 2011 , 2011, Prenatal diagnosis.

[3]  H. Cuckle,et al.  Multi‐Marker Maternal Serum Screening for Chromosomal Abnormalities , 2010 .

[4]  R. Bahado-Singh,et al.  An overview of first-trimester screening for chromosomal abnormalities. , 2010, Clinics in laboratory medicine.

[5]  J. Egan,et al.  The role of second-trimester serum screening in the post-first-trimester screening era. , 2010, Clinics in laboratory medicine.

[6]  G. Calabrese,et al.  Effectiveness of crosstrimester test in selecting high‐risk pregnant women to undergo invasive prenatal diagnosis , 2010, Prenatal diagnosis.

[7]  B. Benacerraf.  The history of the second‐trimester sonographic markers for detecting fetal Down syndrome, and their current role in obstetric practice , 2010, Prenatal diagnosis.

[8]  F. Malone,et al.  Role of Second-Trimester Genetic Sonography After Down Syndrome Screening , 2009, Obstetrics and gynecology.

[9]  F. Malone,et al.  Contingent screening for Down syndrome—results from the FaSTER trial , 2008, Prenatal diagnosis.

[10]  J. Egan,et al.  Stepwise sequential screening for fetal aneuploidy. , 2007, American journal of obstetrics and gynecology.

[11]  A. Rudnicka,et al.  Sequential and contingent prenatal screening for Down syndrome , 2006, Prenatal diagnosis.

[12]  A. Rudnicka,et al.  First-trimester or second-trimester screening, or both, for Down's syndrome. , 2005, The New England journal of medicine.

[13]  H. Cuckle,et al.  Practical strategies in contingent sequential screening for Down syndrome , 2005, Prenatal diagnosis.

[14]  K. Ritchie,et al.  Contingent screening for Down syndrome is an efficient alternative to non‐disclosure sequential screening , 2004, Prenatal diagnosis.

[15]  J. Haddow,et al.  Maternal serum–integrated screening for trisomy 18 using both first‐ and second‐trimester markers , 2003, Prenatal diagnosis.

[16]  S. Cicero,et al.  Screening for triploidy by fetal nuchal translucency and maternal serum free β‐hCG and PAPP‐A at 10–14 weeks of gestation , 2000, Prenatal diagnosis.

[17]  K. Spencer,et al.  Screening for trisomy 18 by fetal nuchal translucency and maternal serum free β ‐hCG and PAPP‐A at 10–14 weeks of gestation , 1999, Prenatal diagnosis.

[18]  N. Wald,et al.  Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. , 1999, The New England journal of medicine.

[19]  T. Jenkins,et al.  Integrated screening for Down's syndrome. , 1999, The New England journal of medicine.

[20]  K. Nicolaides,et al.  Prenatal diagnosis of trisomy 18 at the 10–14‐week ultrasound scan , 1997, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[21]  J. Canick,et al.  Risk‐based prenatal screening for trisomy 18 using alpha‐fetoprotein, unconjugated oestriol and human chorionic gonadotropin , 1995, Prenatal diagnosis.

[22]  A. Pazarbasi,et al.  [Prenatal diagnosis]. , 1994, Revista chilena de obstetricia y ginecologia.